PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 22512726-5 2013 The effects of paclitaxel, cyclophosphamide, and gemcitabine, are antineoplastic agents, were examined on the in vitro enzyme activity of glutathione S-transferase and were determined to be inhibitors for the enzyme. Cyclophosphamide 27-43 glutathione S-transferase kappa 1 Homo sapiens 138-163 22012257-1 2012 PURPOSE: The cytotoxic drug cyclophosphamide (CP) is bioactivated into 4-hydroxy-cyclophosphamide (4-OH-CP) through cytochrome P450 enzymes and cleared through aldehyde dehydrogenase and glutathione S-transferase. Cyclophosphamide 28-44 glutathione S-transferase kappa 1 Homo sapiens 187-212 23252950-4 2013 Moreover, glutathione-S-transferase isoenzymes have been associated with cellular outward transport of various alkylating agents, including Cy metabolites, melphalan, Bu and chlorambucil. Cyclophosphamide 140-142 glutathione S-transferase kappa 1 Homo sapiens 10-35 7954469-0 1994 Involvement of human glutathione S-transferase isoenzymes in the conjugation of cyclophosphamide metabolites with glutathione. Cyclophosphamide 80-96 glutathione S-transferase kappa 1 Homo sapiens 21-46 18496131-1 2008 PURPOSE: The anticancer agent, cyclophosphamide, is metabolized by cytochrome P450 (CYP), glutathione S-transferase (GST) and aldehyde dehydrogenase (ALDH) enzymes. Cyclophosphamide 31-47 glutathione S-transferase kappa 1 Homo sapiens 90-115 18496131-1 2008 PURPOSE: The anticancer agent, cyclophosphamide, is metabolized by cytochrome P450 (CYP), glutathione S-transferase (GST) and aldehyde dehydrogenase (ALDH) enzymes. Cyclophosphamide 31-47 glutathione S-transferase kappa 1 Homo sapiens 117-120 16995867-0 2006 Relationship of glutathione S-transferase genotypes with side-effects of pulsed cyclophosphamide therapy in patients with systemic lupus erythematosus. Cyclophosphamide 80-96 glutathione S-transferase kappa 1 Homo sapiens 16-41 15142875-2 2004 Busulfan, as well as the metabolites of cyclophosphamide, are conjugated with glutathione (GSH), catalyzed by enzymes of the glutathione S-transferase (GST) family. Cyclophosphamide 40-56 glutathione S-transferase kappa 1 Homo sapiens 125-150 15142875-2 2004 Busulfan, as well as the metabolites of cyclophosphamide, are conjugated with glutathione (GSH), catalyzed by enzymes of the glutathione S-transferase (GST) family. Cyclophosphamide 40-56 glutathione S-transferase kappa 1 Homo sapiens 152-155 12516103-2 2003 A recently described polymorphism alters hepatic expression of GSTA1, a GST with high activity in glutathione conjugation of metabolites of cyclophosphamide (CP). Cyclophosphamide 140-156 glutathione S-transferase kappa 1 Homo sapiens 63-66 7786310-2 1995 The role of other drug-metabolizing enzymes such as glutathione S-transferase (GST) in CPA resistance is, however, less certain. Cyclophosphamide 87-90 glutathione S-transferase kappa 1 Homo sapiens 52-77 7786310-2 1995 The role of other drug-metabolizing enzymes such as glutathione S-transferase (GST) in CPA resistance is, however, less certain. Cyclophosphamide 87-90 glutathione S-transferase kappa 1 Homo sapiens 79-82 7786310-9 1995 These studies establish that in addition to ALDH, GST overexpression can contribute to acquired resistance of tumor cells to 4HC and, furthermore, suggest that modulators that target the GSH/GST system could be useful in overcoming CPA resistance in the clinic. Cyclophosphamide 232-235 glutathione S-transferase kappa 1 Homo sapiens 50-53 7786310-9 1995 These studies establish that in addition to ALDH, GST overexpression can contribute to acquired resistance of tumor cells to 4HC and, furthermore, suggest that modulators that target the GSH/GST system could be useful in overcoming CPA resistance in the clinic. Cyclophosphamide 232-235 glutathione S-transferase kappa 1 Homo sapiens 191-194 7954469-13 1994 Since all of the human GSTs tested did catalyze the formation of 4-GSCP, the role of 4-GSCP either as a transport form of activated cyclophosphamide or as a detoxification product is discussed. Cyclophosphamide 132-148 glutathione S-transferase kappa 1 Homo sapiens 23-27 7954469-3 1994 However, little is known about the GSH-/GST-dependent biotransformation of alkylating agents, including cyclophosphamide. Cyclophosphamide 104-120 glutathione S-transferase kappa 1 Homo sapiens 40-43 1419639-0 1992 Glutathione S-transferase activity and isoenzyme composition in benign ovarian tumours, untreated malignant ovarian tumours, and malignant ovarian tumours after platinum/cyclophosphamide chemotherapy. Cyclophosphamide 170-186 glutathione S-transferase kappa 1 Homo sapiens 0-25 7728738-3 1994 Acrolein and phosphoramide mustard are the metabolites of cyclophosphamide which are among the causative agents which reduce the activity of superoxide dismultase, catalase, glutathione peroxidase, glutathione reductase, glutathione-S-transferase and glucose-6-phosphate dehydrogenase in erythrocytes of CMF treated breast cancer patients. Cyclophosphamide 58-74 glutathione S-transferase kappa 1 Homo sapiens 221-246 1419639-4 1992 GST isoenzyme patterns were identical in benign tumours and malignant tumours before and after platinum/cyclophosphamide chemotherapy, while GST pi was the predominant transferase. Cyclophosphamide 104-120 glutathione S-transferase kappa 1 Homo sapiens 0-3 1419639-5 1992 Mean GST activity and GST pi amount were decreased (P < 0.05) in malignant ovarian tumours after platinum/cyclophosphamide chemotherapy compared to untreated ovarian malignant tumours. Cyclophosphamide 109-125 glutathione S-transferase kappa 1 Homo sapiens 22-25 1680689-14 1991 Cyclophosphamide (CP) resistance has been attributed to an increased activity of two different enzymes, glutathione S-transferase, also involved in MDR phenotype, and aldehyde dehydrogenase, which catalyzes inactivation of CP in non cytotoxic metabolites. Cyclophosphamide 0-16 glutathione S-transferase kappa 1 Homo sapiens 104-129 31773494-0 2020 Correction to: Analysis of glutathione S-transferase and cytochrome P450 gene polymorphism in recipients of dose-adjusted busulfan-cyclophosphamide conditioning. Cyclophosphamide 122-147 glutathione S-transferase kappa 1 Homo sapiens 27-52 27002825-0 2016 Glutathione S Transferases Polymorphisms Are Independent Prognostic Factors in Lupus Nephritis Treated with Cyclophosphamide. Cyclophosphamide 108-124 glutathione S-transferase kappa 1 Homo sapiens 0-26 27002825-1 2016 OBJECTIVE: To investigate association between genetic polymorphisms of GST, CYP and renal outcome or occurrence of adverse drug reactions (ADRs) in lupus nephritis (LN) treated with cyclophosphamide (CYC). Cyclophosphamide 182-198 glutathione S-transferase kappa 1 Homo sapiens 71-74 27002825-1 2016 OBJECTIVE: To investigate association between genetic polymorphisms of GST, CYP and renal outcome or occurrence of adverse drug reactions (ADRs) in lupus nephritis (LN) treated with cyclophosphamide (CYC). Cyclophosphamide 200-203 glutathione S-transferase kappa 1 Homo sapiens 71-74